Claret Medical Inc. won FDA clearance for its Sentinel device to capture debris from a transcatheter aortic valve replacement (TAVR) and reduce risk of stroke. Touted by the Santa Rosa, Calif.-based company as the first of its kind in the U.S., the device blocks microphages, fibrin and cholesterol materials loosened during the procedure which can then travel to the brain.